The effectiveness of esophageal peristaltic suppression using an intravenous drip of scopolamine butylbromide for endoscopic injection sclerotherapy of esophageal varices

The effectiveness of esophageal peristaltic suppression using an intravenous drip of scopolamine butylbromide for endoscopic injection sclerotherapy of esophageal varices - The effectiveness of esophageal peristaltic suppression using an intravenous drip of antispasmodic for endoscopic injection sclerotherapy of esophageal varices

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036430

Enrollment

Registered

2019-04-06

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal varices

Interventions

Patients who are enrolled will receive conventional sclerotherapy (1 week / week, 3 times a course), and both groups will first receive an intravenous injection of 10 mg of butylscopolamine bromide at

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are considered for the treatment of esophageal varices, will undergo prophylactic sclerotherapy and meet the criteria below. 1 Men and women over 20 years of age 2Patients who perform endoscopic sclerotherapy prophylactically for esophageal varices 3 Patients who gave written informed consent and obtained written informed consent for study participation

Exclusion criteria

Exclusion criteria: 1 Patients with hypersensitivity symptoms and contraindications in anticonvulsants used 2 Patients who are difficult to participate in this study due to the merger of serious liver disease, kidney disease, heart disease etc. 3 Pregnant women, lactating women or women who may be pregnant 4 Patients who are considered inappropriate by the research director or researcher for this study

Design outcomes

Primary

Measure	Time frame
Fixation time of the puncture needle	—

Countries

Japan

Contacts

Public ContactKayo Sakai

Iizuka Hospital Gastroenterology

ktokumaruh2@aih-net.com0948-22-3800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026